Literature DB >> 24607884

Early axonal loss accompanied by impaired endocytosis, abnormal axonal transport, and decreased microtubule stability occur in the model of Krabbe's disease.

Carla Andreia Teixeira1, Catarina Oliveira Miranda2, Vera Filipe Sousa2, Telma Emanuela Santos1, Ana Rita Malheiro1, Melani Solomon3, Gustavo H Maegawa3, Pedro Brites1, Mónica Mendes Sousa4.   

Abstract

In Krabbe's disease (KD), a leukodystrophy caused by β-galactosylceramidase deficiency, demyelination and a myelin-independent axonopathy contributes to the severe neuropathology. Beyond axonopathy, we show that in Twitcher mice, a model of KD, a decreased number of axons both in the PNS and in the CNS, and of neurons in dorsal root ganglia (DRG), occurred before the onset of demyelination. Despite the early axonal loss, and although in vitro Twitcher neurites degenerated over time, Twitcher DRG neurons displayed an initial neurite overgrowth and, following sciatic nerve injury, Twitcher axons were regeneration-competent, at a time point where axonopathy was already ongoing. Psychosine, the toxic substrate that accumulates in KD, induced lipid raft clustering. At the mechanistic level, TrkA recruitment to lipid rafts was dysregulated in Twitcher neurons, and defective activation of the ERK1/2 and AKT pathways was identified. Besides defective recruitment of signaling molecules to lipid rafts, the early steps of endocytosis and the transport of endocytic and synaptic vesicles were impaired in Twitcher DRG neurons. Defects in axonal transport, specifically in the retrograde component, correlated with decreased levels of dynein, abnormal levels of post-translational tubulin modifications and decreased microtubule stability. The identification of the axonal defects that precede demyelination in KD, together with the finding that Twitcher axons are regeneration-competent when axonopathy is already installed, opens new windows of action to effectively correct the neuropathology that characterizes this disorder.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Axonal transport; Endocytosis; Krabbe's disease; Leukodystrophy; Myelin; Twitcher

Mesh:

Substances:

Year:  2014        PMID: 24607884      PMCID: PMC4307018          DOI: 10.1016/j.nbd.2014.02.012

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  47 in total

1.  Fibrin inhibits peripheral nerve remyelination by regulating Schwann cell differentiation.

Authors:  Katerina Akassoglou; Wei Ming Yu; Pinar Akpinar; Sidney Strickland
Journal:  Neuron       Date:  2002-03-14       Impact factor: 17.173

2.  Primary bone marrow mesenchymal stromal cells rescue the axonal phenotype of Twitcher mice.

Authors:  Catarina Oliveira Miranda; Carla Andreia Teixeira; Vera Filipe Sousa; Telma Emanuela Santos; Márcia Almeida Liz; Ana Maio Marques; Perpétua Pinto-do-Ó; Mónica Mendes Sousa
Journal:  Cell Transplant       Date:  2013-06-27       Impact factor: 4.064

3.  In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation.

Authors:  Akihisa Matsuyama; Tadahiro Shimazu; Yuko Sumida; Akiko Saito; Yasuhiro Yoshimatsu; Daphné Seigneurin-Berny; Hiroyuki Osada; Yasuhiko Komatsu; Norikazu Nishino; Saadi Khochbin; Sueharu Horinouchi; Minoru Yoshida
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

Review 4.  Membrane traffic in sphingolipid storage diseases.

Authors:  R E Pagano; V Puri; M Dominguez; D L Marks
Journal:  Traffic       Date:  2000-11       Impact factor: 6.215

5.  Jamming the endosomal system: lipid rafts and lysosomal storage diseases.

Authors:  K Simons; J Gruenberg
Journal:  Trends Cell Biol       Date:  2000-11       Impact factor: 20.808

Review 6.  Lipid rafts in neuronal signaling and function.

Authors:  Brian A Tsui-Pierchala; Mario Encinas; Jeffrey Milbrandt; Eugene M Johnson
Journal:  Trends Neurosci       Date:  2002-08       Impact factor: 13.837

7.  Characterization and application of a disease-cell model for a neurodegenerative lysosomal disease.

Authors:  Jameson J Ribbens; Ann B Moser; Walter C Hubbard; Ernesto R Bongarzone; Gustavo H B Maegawa
Journal:  Mol Genet Metab       Date:  2013-09-21       Impact factor: 4.797

8.  The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3β and deregulation of molecular motors.

Authors:  Ludovico Cantuti Castelvetri; Maria I Givogri; Amy Hebert; Benjamin Smith; Yuyu Song; Agnieszka Kaminska; Aurora Lopez-Rosas; Gerardo Morfini; Gustavo Pigino; Mark Sands; Scott T Brady; Ernesto R Bongarzone
Journal:  J Neurosci       Date:  2013-06-12       Impact factor: 6.167

9.  Trk activation of the ERK1/2 kinase pathway stimulates intermediate chain phosphorylation and recruits cytoplasmic dynein to signaling endosomes for retrograde axonal transport.

Authors:  David J Mitchell; Kiev R Blasier; Erin D Jeffery; Mitchell W Ross; Ashok K Pullikuth; Dong Suo; Juyeon Park; W Russell Smiley; Kevin W-H Lo; Jeffrey Shabanowitz; Christopher D Deppmann; Jonathan C Trinidad; Donald F Hunt; Andrew D Catling; K Kevin Pfister
Journal:  J Neurosci       Date:  2012-10-31       Impact factor: 6.167

10.  Peripheral neuropathy with hypomyelinating features in adult-onset Krabbe's disease.

Authors:  M Sabatelli; L Quaranta; F Madia; G Lippi; A Conte; M Lo Monaco; G Di Trapani; M A Rafi; D A Wenger; A M Vaccaro; P Tonali
Journal:  Neuromuscul Disord       Date:  2002-05       Impact factor: 4.296

View more
  30 in total

Review 1.  Lysosphingolipids and sphingolipidoses: Psychosine in Krabbe's disease.

Authors:  Stefka Spassieva; Erhard Bieberich
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 2.  Treatment for Krabbe's disease: Finding the combination.

Authors:  Christina R Mikulka; Mark S Sands
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 3.  How membrane dysfunction influences neuronal survival pathways in sphingolipid storage disorders.

Authors:  Tuba Sural-Fehr; Ernesto R Bongarzone
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

4.  δ-Tocopherol Effect on Endocytosis and Its Combination with Enzyme Replacement Therapy for Lysosomal Disorders: A New Type of Drug Interaction?

Authors:  Rachel L Manthe; Jeffrey A Rappaport; Yan Long; Melani Solomon; Vinay Veluvolu; Michael Hildreth; Dencho Gugutkov; Juan Marugan; Wei Zheng; Silvia Muro
Journal:  J Pharmacol Exp Ther       Date:  2019-05-17       Impact factor: 4.030

Review 5.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

6.  Quantitative Microproteomics Based Characterization of the Central and Peripheral Nervous System of a Mouse Model of Krabbe Disease.

Authors:  Davide Pellegrini; Ambra Del Grosso; Lucia Angella; Nadia Giordano; Marialaura Dilillo; Ilaria Tonazzini; Matteo Caleo; Marco Cecchini; Liam A McDonnell
Journal:  Mol Cell Proteomics       Date:  2019-03-29       Impact factor: 5.911

7.  Mechanism of neuromuscular dysfunction in Krabbe disease.

Authors:  Ludovico Cantuti-Castelvetri; Erick Maravilla; Michael Marshall; Tammy Tamayo; Ludovic D'auria; John Monge; James Jeffries; Tuba Sural-Fehr; Aurora Lopez-Rosas; Guannan Li; Kelly Garcia; Richard van Breemen; Charles Vite; Jesus Garcia; Ernesto R Bongarzone
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

8.  Synaptic failure: The achilles tendon of sphingolipidoses.

Authors:  Ludovico Cantuti-Castelvetri; Ernesto R Bongarzone
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

9.  Midbrain morphology reflects extent of brain damage in Krabbe disease.

Authors:  Giulio Zuccoli; Srikala Narayanan; Ashok Panigrahy; Michele D Poe; Maria L Escolar
Journal:  Neuroradiology       Date:  2015-04-10       Impact factor: 2.804

10.  Long-Term Improvement of Neurological Signs and Metabolic Dysfunction in a Mouse Model of Krabbe's Disease after Global Gene Therapy.

Authors:  Michael S Marshall; Yazan Issa; Benas Jakubauskas; Monika Stoskute; Vince Elackattu; Jeffrey N Marshall; Wil Bogue; Duc Nguyen; Zane Hauck; Emily Rue; Subha Karumuthil-Melethil; Violeta Zaric; Maarten Bosland; Richard B van Breemen; Maria I Givogri; Steven J Gray; Stephen J Crocker; Ernesto R Bongarzone
Journal:  Mol Ther       Date:  2018-01-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.